呼吸器
- SARS-CoV-2 中和抗体ソトロビマブによる Covid-19 の早期治療Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
- Covid-19 の高リスク外来患者に対する早期の回復者血漿Early Convalescent Plasma for High-Risk Outpatients with Covid-19
- BNT162b2 mRNA Covid-19 ワクチンの 6 ヵ月間の安全性と有効性Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
- mRNA-1273 SARS-CoV-2 ワクチンの盲検期終了時点における有効性Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
- 重症喘息に対するリサンキズマブ ― 第 2a 相プラセボ対照試験Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial
- ワクチン起因性免疫性血小板減少症/血栓症の臨床像Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis
- 中等症～重症喘息患者に対するイテペキマブの有効性と安全性Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
- Covid-19 ワクチン接種を完了した医療従事者におけるブレイクスルー感染Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
- 外来診療および入院診療の場における Covid-19 ワクチンの有効性Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
- 軽症または中等症の Covid-19 に対するバムラニビマブとエテセビマブの併用Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19